Astaxanthin ameliorates prenatal LPS-exposed behavioral deficits and oxidative stress in adult offspring

Md. Mamun Al-Amin1,2, Rabeya Sultana1, Sharmin Sultana1, Md. Mahbubur Rahman1 and Hasan Mahmud Reza1*

Abstract

**Background:** Prenatal maternal lipopolysaccharide (LPS) exposure leads to behavioral deficits such as depression, anxiety, and schizophrenia in the adult lives. LPS-exposure resulted in the production of cytokines and oxidative damage. On the contrary, astaxanthin is a carotenoid compound, showed neuroprotective properties via its antioxidant capacity. This study examines the effect of astaxanthin on the prenatal maternal LPS-induced postnatal behavioral deficit in mice.

**Results:** We found that prenatal LPS-exposed mice showed extensive immobile phase in the tail suspension test, higher frequent head dipping in the hole-board test and greater hypolocomotion in the open field test. All these values were statistically significant (p < 0.05). In addition, a marked elevation of the level of lipid peroxidation, advanced protein oxidation product, nitric oxide, while a pronounced depletion of antioxidant enzymes (superoxide dismutase, catalase and glutathione) were observed in the adult offspring mice that were prenatally exposed to LPS. To the contrary, 6-weeks long treatment with astaxanthin significantly improved all behavioral deficits (p < 0.05) and diminished prenatal LPS-induced oxidative stress markers in the brain and liver.

**Conclusions:** Taken together, these results suggest that prenatal maternal LPS-exposure leads to behavioral deficits in the adults, while astaxanthin ameliorates the behavioral deficits presumably via its antioxidant property.

**Keywords:** Astaxanthin, Lipopolysaccharide, Depression, Anxiety, Oxidative stress

Background

Administration of lipopolysaccharide (LPS) into pregnant rodents strongly impaired innate immune responses [1] without the presence of infection [2]. LPS has been widely used in rodents during pregnancy to study behavioral deficits and histological irregularities in the adult offspring [3–6]. Prenatal maternal LPS challenge increases pro-inflammatory cytokines that cross the placental barrier and interfere with the early stages of brain development. The developmental abnormality is expressed in the behavioral level during the adult stage of life. Human epidemiological data suggests, early infections can produce mental disorders [7].

Prenatal LPS-induced maternal immune activation model has been used to develop animal model of depression [8], anxiety [9–11], impairment in learning and memory [12, 13], schizophrenia [14–16] and autism [17, 18]. In addition, prenatal LPS-exposure is linked with the development of long-term physiological complications in the offspring animals [19]. During gestational period, a specific time window is critical in inducing neurodevelopmental disorder and impaired behavioral deficits in the rodent’s offspring [6]. In this window, LPS-exposure leads to produce cytokines that crosses the placental barrier, which in turn interrupts the processes of fetal brain development [20]. Prenatal LPS-exposure has shown to enhance the level of nitric oxide (NO), lipid peroxidation
and depleted the level of glutathione in the maternal liver, embryo, and placenta [21]. LPS-induced intrauterine fetal death and growth restriction are associated with higher lipid peroxidation and glutathione depletion in maternal liver, placenta, and fetal liver [22]. Cytokine independent reactive oxygen species (ROS) production has also been reported even within 40 min after LPS stimulation to human umbilical vein endothelial cells [23].

Based on the current data, it is hypothesized that prenatal LPS administration may contribute to adult behavioral dysfunction. It is also thought that ROS might play a significant role in the progression of such dysfunction. We assume that antioxidant like astaxanthin may scavenge oxidative stress in the brain to improve the impaired brain function. Therefore, this study investigates (i) the effect of prenatal maternal LPS-exposed behavioral disorders and oxidative damage in the adult offspring and (ii) the effect of a potential antioxidant (astaxanthin) treatment in this prenatal LPS-exposed model.

Previous study used LPS at various dose range including small (120 µg/kg, i.p.) at GD 15–17 [24], moderate (300 µg/kg, i.p.) at GD 16–17 [12] to high (800 µg/kg, i.p.) at GD 15–17 [25] in mice model of behavioral deficit. In this study, moderate dose of LPS (300 µg/kg, body weight) was selected for *Swiss albino* mice. On the contrary, astaxanthin (AST) is a carotenoid antioxidant, having 100–500 times greater antioxidant capacity than α-tocopherol [26]. The BBB crossing ability of AST was evident, and possess neuroprotective properties [27] by the restoration of antioxidant enzymes such as, superoxide dismutase and glutathione peroxidase, and reduction of lipid peroxidation (MDA) [28], down-regulation of increased nuclear factor-kappaB (NF-κB), and expression of inflammatory cytokines [29]. Moreover, astaxanthin treatment improves depressive-like behavior by reducing the level of IL-6 and IL-β in the frontal cortex [30]. AST has shown a dose-dependent anti-inflammatory effect, by suppressing NO, and tumor necrosis factor-α (TNF-α) production, through directly blocking nitric oxide synthase enzyme activity. It is hypothesized that AST might be an effective antioxidant treatment of choice to improve LPS-exposed oxidative stress in adult lives.

**Methods**

**Animals**

Adult (age: 6 months) female (*n* = 12) *Swiss albino* mice (weight: 30 ± 2 g) were used for this experiment. Animals were housed in animal cage (Tecniplast, Italy) at 21 ± 2 °C room temperature, relative humidity 55 ± 5 % and 12-h light/dark cycle; and feed pellets and water ad libitum. Females with vaginal plug were designated as on embryonic day (ED) 0. The experimental procedure was reviewed and approved by the institutional ethical committee at the Department of Pharmaceutical Sciences, North South University (NSU/PHA/2014/133-046), Dhaka, Bangladesh. Animals were handled in accordance with the international principles guiding the usage and handling of experimental animals (United States National Institute for Health Publication, 1985). Behavioral and neuroendocrine parameters might be influenced by different estrous cycle phases [31]. Therefore, estrous cycle in female offspring was monitored before deciding the day for behavioral test.

**Animal grouping**

Female pregnant mice were divided into two groups at ED 16 and ED 17. *Control_saline* group (*n* = 6) received intraperitoneal water for injection (100 µl) (Fig. 1) and experimental group (*n* = 6) received intraperitoneal LPS (*Escherichia coli*, Sigma-Aldrich, USA) at a dose of 300 µg/kg, body weight. Forty pups were selected for the postnatal experiments. On postnatal day 23 offspring were weaned and separated based on the gender. Offspring male animals were randomly selected and further grouped into four on postnatal day (PD) 90 as- (i) *control_saline* (*n* = 10), (ii) *control_AST* (*n* = 10), (iii) LPS (*n* = 10) and (iv) LPS_AST (*n* = 10).

Control mice received either oral saline (100 µl) or oral astaxanthin (2 mg/kg, body weight; while LPS group was exposed to prenatal LPS and later received either oral saline (100 µl) or oral astaxanthin (2 mg/kg, body weight for 6 weeks). Behavioral test was conducted within 3 days (PD 133, 134 and 135) in the order of open field test followed by tail suspension and hole-board test. Within this period we have not seen any estrous cycle that may affect our behavioral results. Earlier, we decided to extend the treatment period (astaxanthin) if estrous cycle would appear. At the end of the behavioral test, animals were sacrificed to collect tissue.

**Preparation of astaxanthin and lipopolysaccharide**

LPS (300 µg/kg) from *E. coli*, Sigma Aldrich, USA was dissolved in sterile water for injection [32] while water for injection (100 µL) was purchased from pharmacy shops. Astaxanthin powder was received as a gift from Pharma raw Bangladesh. AST was dissolved in distilled water at a concentration of 600 µg/ml and administered orally at a dose of 2 mg/kg body weight; [33] for 6 weeks starting from PD 91 to PD132.

**Behavioral test**

**Open field test**

The open field test device was made of plastic wood material following measurements described earlier [34]. The light source was a 35 w bulb suspended approximately 1 m above the apparatus for background lighting. Mice
were carried to the testing room in their home cages and handled by the tails and were placed in the apparatus and allowed to explore the field for 20 min. After each trial, apparatus was cleaned using 70 % ethanol and allowed to dry. The exploration was recorded for later analysis by using a Logitech™ 4mp webcam. Video was analyzed manually using Smart™ V 3.0 video tracking software developed by PanLab. During the analysis, center zone and periphery zone were defined where center zone consists of 34.5 × 34.5 cm.

**Hole-board test**

Hole-board test device box was constructed using plastic wood (length: 42 cm, width: 42 cm, height: 30 cm) containing twenty holes (4 cm diameter) in the floor. We considered gross exploratory behavior as the number of head dips into the holes (placing the head or snout into the holes in the floor). Video camera was installed to record the frequency and duration of each dipping. Locomotion-related behavior was scored as the number of rearings. The hole-board was cleaned between sessions.

**Tail suspension test**

Tail suspension test (TST) was conducted according to the previous procedure described [35]. Briefly, each mouse was suspended by its tail using a clamp, 2 cm from the distal end, for 5 min in a gray plastic box (40 cm high, 30 cm wide, and 20 cm deep), with the head about above the floor (60 cm). Duration of immobility (defined as the absence of all movement except for those required for respiration) and mobility time were recorded (in seconds) for 5 min. Animals that climbed their tails during TST were excluded. Mobility was termed as hind leg movement, while immobility was defined as the absence of whole-body movement.

**Tissue processing**

Brain and liver tissues were processed according to our previous method [36]. Mice were anesthetized with 0.1 ml of ketamine (50 mg/ml) and perfused through the heart with cold 0.9 % NaCl and phosphate buffered saline (PBS) to remove blood from the brain and liver tissue. The whole brain was immediately removed and kept in a petridish containing saline on ice. Cortex (100 mg) regions from the brain and liver (100 mg) tissues were collected to prepare 10 % (w/v) homogenate in sodium phosphate buffer (30 mmol/l, pH 7.0) using Ultra-Turrax T25 (USA) homogenizer. Homogenized tissue samples were sonicated at 5 s cycle for 150 s using an ultrasonic processor.

**Oxidative stress estimation**

**Lipid peroxidation (MDA)**

Lipid peroxidation was estimated colorimetrically measuring thiobarbituric acid reactive substances (TBARS)
as described previously [37]. Briefly, tissue homogenate (0.1 ml + Tris–HCl buffer, pH 7.5) was treated with 2 ml of (1:1 ratio) TBA-TCA-HCl reagent (thiobarbituric acid 0.37 %, 0.25 N HCl and 15 % TCA) and placed in water bath for 30 min and cooled. The absorbance of clear supernatant was measured against reference blank at 535 nm.

Catalase (CAT)
Activity of catalase (CAT) enzyme was assayed at 240 nm and expressed as activity in percentage of H2O2 consumed/min/mg protein as described [38]. The reaction mixture (1.5 ml) contained phosphate buffer (1.0 ml) (0.01 M, pH 7.0), tissue homogenate (0.1 ml supernatant) and H2O2 (0.4 ml) (2 M). The reaction was stopped by the addition of 2.0 ml of dichromate-acetic acid reagent (5 % potassium dichromate and glacial acetic acid were mixed in 1:3 ratio).

Nitric oxide (NO)
Nitric oxide was determined according to the method described by Tracy et al. as nitrate and nitrite [39]. NO level was measured by using standard curve and expressed as nmol/gm of tissue. Griess-Ilosvoy reagent was modified by using naphthyl ethylene diaminedi-hydrochloride (NED) (0.1 % w/v) instead of 1-naphthylamine (5 %). The reaction mixture (3 ml) containing brain homogenates (0.5 ml), phosphate buffer saline (0.5 ml), NED (1 ml) and sulfanilamide (1 ml) was incubated at 25 °C for 15 min. A pink chromophore was formed in diffused light. The absorbance of the solution was measured at 540 nm against the corresponding blank solution.

Advanced protein oxidation product (APOP)
Advanced protein oxidation product was assayed based on spectrophotometric detection according to [40]. APOPs were expressed in chloramine units (nmol/ml). Briefly, plasma (50 µl diluted with phosphate-buffered saline (PBS) (100 µl), and chloramine T (0–100 mmol/l) were used for the preparation of calibration curve and PBS was used as blank. Potassium iodide (100 µl of 1.16 M) and acetic acid (50 µl) were added to each well and absorbance was taken at 340 nm immediately.

Superoxide dismutase (SOD)
The activity of superoxide dismutase enzyme was assayed by a modified procedure described previously [41]. Briefly, each 300 µl reaction mixture contained 50 mM sodium phosphate (pH 7.8), 13 mM methionine, 75 mM nitrobluetetrazolium (NBT), 2 mM riboflavin, 100 mM EDTA, and 2 ml of plasma. The change of absorbance in each sample was then recorded at 560 nm after the production of blue formazan.

Glutathione (GSH)
Glutathione in the brain was assayed according to the previous method [42]. Briefly, 1 ml of plasma was added with 2.7 ml of phosphate buffer (0.1 mol/l, pH 8) and 0.2 ml of 5, 5-dithio-bis (2-nitrobenzoic acid). The color developed was measured immediately at 412 nm. Results are expressed as µmol/mg protein.

Statistics
The data of this present study was analyzed by one-way ANOVA to compare the main effect of astaxanthin on dependent variables in control_saline, control_AST, LPS, and LPS_AST groups. Post-hoc test namely “Newman-Keuls” was used as a multiple comparisons test to compare between groups. All analyses were carried out using GraphPad Prism software (version 6.0). The differences were considered significant when p values were at least less than 0.05. Data are represented as mean ± SEM (standard error of the mean).

Results
Behavioral studies
Open field test
A significant main effect of treatment on the number of entry into the periphery [F(3,36) = 6.34, p < 0.01] (Fig. 2a), time spent in periphery [F(3,33) = 6.95, p < 0.001] (Fig. 2b) and total distance travelled [F(3,34) = 4.49, p < 0.01] (Fig. 2c) was observed for four conditions (control_saline, LPS, LPS_AST, control_AST). Neuman-keuls multiple comparison test showed that control_saline (M = 29.50, SD = 10.33), LPS_AST (M = 32.70, SD = 15.09) and control_AST (M = 44.50, SD = 18.45) groups had lower entry frequency in the periphery than LPS group (M = 63.10, SD = 27.99). Similarly LPS group (M = 949, SD = 147) spent longer time in periphery than control_saline (M = 695, SD = 167), LPS_AST (M = 804, SD = 141) and control_AST (M = 678, SD = 126) groups. Moreover, LPS group (M = 213, SD = 46) travelled lower distance than control_saline (M = 320, SD = 96), LPS_AST (M = 328, SD = 36) and control_AST (M = 301, SD = 133) groups.

Tail suspension test
There was a significant main effect of treatment on the duration of immobile time [F(3,34) = 7.39, p < 0.001], and mobile time [F(3,35) = 4.17, p < 0.01] for the four conditions (control_saline, LPS, LPS_AST, control_AST). Neuman-keuls multiple comparison test showed that control_saline (M = 179, SD = 47), LPS_AST (M = 172, SD = 67) and control_AST (M = 219, SD = 47) groups had lower immobile phase than LPS group (M = 269, SD = 39) (Fig. 3a). Likewise, control_saline (M = 167, SD = 43) and LPS_AST (M = 154, SD = 66) spent less...
mobile phase than LPS group (M = 91, SD = 39) (Fig. 3b).
However, control_AST (M = 125, SD = 52) group did not show significant difference from any other groups.

**Hole-board test**
There was a significant main effect of head dipping frequency [F (3,34) = 8.69, p < 0.001] (Fig. 3c) and head dipping duration [F (3,36) = 9.86, p < 0.001] (Fig. 3d). Neurman-keuls multiple comparison test showed that control_saline (M = 43.0, SD = 6.5), LPS_AST (M = 46.3, SD = 4.3) and control_AST (M = 52.6, SD = 8.1) groups had lower frequency of head dipping than LPS group (M = 65.0, SD = 16.8). Additionally, control_saline (M = 81.8, SD = 27.2), LPS_AST (M = 76.7, SD = 20.1) and control_AST (M = 84.4, SD = 18.6) groups spent lower duration of head dipping than LPS group (M = 125.0, SD = 22.6).

**Oxidative stress**
One-way ANOVA analysis showed a significant main effect of treatment on the MDA level in brain [F (3,36) = 6.19, p < 0.001] (Fig. 4a), and liver [F (3,35) = 4.37, p < 0.01] (Fig. 4b); AOPP in the brain [F (3,34) = 5.27, p = 0.01] (Fig. 4c), and liver [F (3,34) = 18.06, p = 0.001] (Fig. 4d); NO in the brain [F (3,33) = 40.47, p < 0.001] (Fig. 4e) and liver [F (3,31) = 28.39, p < 0.001] (Fig. 4f); glutathione in the brain [F (3,36) = 266.1, p < 0.001] (Fig. 4g) and liver [F (3,35) = 16.79, p < 0.001] (Fig. 4h); catalase activity in the brain [F (3,34) = 9.45, p < 0.001] (Fig. 4i) and liver [F (3,36) = 16.27, p < 0.001] (Fig. 4j); and SOD activity in the brain [F (3,34) = 6.97, p < 0.001] (Fig. 4k) and liver [F (3,32) = 16.97, p < 0.001] (Fig. 4l) among the four treatment groups.

Neurman-keuls multiple comparison test indicated a lower level of MDA in the control_saline (M = 27.0, SD = 8.5), LPS_AST (M = 32.7, SD = 8.3) and control_AST (M = 29.5, SD = 4.3) groups than LPS (M = 40.7, SD = 8.7) in the brain. Similar findings were observed in liver MDA also. Likewise, lower level of AOPP was found in control_saline (M = 8.0, SD = 25.0), LPS_AST (M = 82.1, SD = 26.1) and control_AST (M = 40.3, SD = 3.5) than LPS (M = 121.6, SD = 12.3) in the brain. Similar findings were again observed in liver NO.

In the contrary, control_saline (M = 3.2, SD = 2.1), LPS_AST (M = 8.3, SD = 1.9) and control_AST (M = 2.4, SD = 1.6) groups had lower NO than LPS (M = 11.2, SD = 2.2) in the brain. Similar results were observed in liver NO as well.

To the contrary, control_saline (M = 11.7, SD = 1.7), LPS_AST (M = 3.5, SD = 0.5) and control_AST
(M = 16.2, SD = 1.7) groups had higher GSH than LPS (M = 1.2, SD = 0.6) in the brain. Interestingly, data from liver showed different result. Control_saline (M = 4.0, SD = 0.8) and LPS_AST (M = 3.2, SD = 1.0) had higher GSH than LPS (M = 2.2, SD = 0.5) and control_AST (M = 1.6, SD = 0.2). The level of CAT in the control_saline (M = 12.3, SD = 3.6), LPS_AST (M = 11.9, SD = 4.1) and control_AST (M = 16.4, SD = 1.5) was higher than LPS (M = 8.3, SD = 2.3) in the brain. Similar findings were further observed in liver CAT. SOD data revealed that control_saline (M = 21.4, SD = 6.5), LPS_AST (M = 21.5, SD = 5.9) and control_AST (M = 25.0, SD = 2.7) groups had higher SOD than LPS (M = 14.4, SD = 2.6) in the brain. Liver SOD levels were similarly consistent with that of the brain.

Discussion

The result of the present study demonstrated that prenatal LPS-exposure leads to anxiety and depressive like behaviors, and oxidative damage in the brain and liver during the adult lives. To the contrary, postnatal treatment with astaxanthin ameliorates impaired behavior and oxidative markers in the prenatal LPS-exposed offspring mice.

It has been demonstrated that prenatal maternal immune activation with LPS elicits behavioral deficits such as reduced locomotor activity [9, 43] and social exploration [44] in the open field test in the adult lives [9]. In this study, prenatal maternal LPS-exposed animals have shown an increased time in the peripheral region and reduced global activity in the open field test. In addition, prenatal LPS-exposed animals have spent an increased immobility and reduced mobility time in the tail suspension test in the offspring. These indicate the development of behavioral deficits in the adult offspring of LPS group. Increased duration of immobility in the tail suspension test was also observed in the prenatally stressed rats [45] and mice [46]. To be noted that, when astaxanthin was given to healthy animals, it further showed similar effects as produced by prenatal LPS. This may be explained as the adverse effect of any potent drug/chemical when given at normal physiology. When the immunity was challenged by prenatal LPS, the therapeutic effect of astaxanthin became noticeable. It is important to note that, 6-weeks-long treatment with astaxanthin improves the parameters of open field and tail suspension test in the offspring animals. Ying et al. (2015) has shown that 10 weeks treatment with...
astaxanthin (25 mg/kg/day, body weight) increases locomotor activity by enhancing total travelling distance in the open field test [30].

Our results demonstrated that prenatal maternal LPS exposure leads to increased anxiety in the adult offspring as evident in the hole-board test. Our results are consistent with previous studies demonstrating that prenatal LPS-exposure in the late gestational stage resulted in increased anxiety and depressed behaviors in the adult mice. Prenatal LPS-exposed mice exhibited a higher level of anxiety as evident even in the postnatal day 240 [47]. To the contrary, treatment with astaxanthin reverses anxiety-like disorder in the mice. Our results are in line with the other studies [48, 49].

Our results depict that prenatally LPS-exposed animals had decreased levels of antioxidant enzymes such as, superoxide dismutase, catalase and glutathione, while an increased level of lipid peroxidation, protein oxidation products, and NO in the adult lives. These results indicated the correlation of prenatal administration of LPS with the oxidative stress in the adult lives. The depletion of antioxidant enzymes have shown by the other studies. For example, LPS-induced depletion of endogenous antioxidant enzymes including superoxide dismutase, catalase has been reported earlier [50].

LPS-induced lipid peroxidation has been shown in vitro [51–53] and in vivo [54] animal studies. It has been revealed that LPS-exposure results in neurotoxicity via microglial activation. In-utero LPS-induction causes the activation of microglia. This activated microglia produces increased level of NO, ROS, and inflammatory cytokines such as TNF-α [55]. Activated microglia and astrocyte cells accelerate iNOS induction which results in the production of ROS. NO may harm oligodendrocytes and myelin which in turn interferes mitochondrial electron transport chain and translocates apoptosis inducing factor [56]. Thereby, oxidative stress may play a vital role in damaging axons via disrupting mitochondrial function. As a result, energy production will be dropped, protein and lipid would be oxidized, microtubule would be degraded, and axonal transport will be interrupted [57].

A recent study reports that axonal damage could be elicited by LPS-mediated microglia activation as well as by H₂O₂-promoted oxidative stress [58].

Prenatal LPS-exposure may lead to the brain damage due to the production of toxic free radicals (·OH) [59], and an increased level of superoxide anion (O₂⁻) in the liver [60]. Free radicals react with the important biological substrates, including DNA, proteins, and lipids, which interrupt cell function and may lead to cell death. It has been reported that LPS induces the activation of microglia [61], reactive astrocyte [62], apoptosis of oligodendrocyte precursors which produces superoxide anion (O₂⁻), and NO and contributes in neurodegeneration [63]. Moreover, LPS treatment triggered the production of ROS which in turn causes neuronal cell death in cortex and hippocampus [64, 65] and loss of dopaminergic neurons in the striatum [66]. ROS causes cellular damage including lipid peroxidation, interrupts the fluidity of membrane. Our result showed an increased MDA level in the prenatal LPS-exposed offspring brain and liver, which is consistent with the previous study [67]. The level of glutathione was dropped in the prenatal LPS-exposed offspring. It is possible because of the action of glutathione against lipid peroxidation since it is responsible to reduce the level of peroxidized phospholipids and cholesterol [68]. Thus, the level of glutathione reserves could be depleted during oxidative stress as we observed in the prenatal LPS-exposure group.

Despite the LPS-induced oxidative damage, our results showed an improvement of oxidative markers after the treatment with astaxanthin in the adult lives. This study measured the concentration of MDA, NO, APOP, GSH and antioxidant enzyme activity (SOD and CAT) in the brain and liver. AST reduces prenatal LPS-induced elevated level of MDA, NO, APOP production and restores the concentration of GSH in the brain and liver. In-vitro studies were conducted to measure the effect of AST on LPS-induced oxidative stress in U937 [53] and RAW264.7 [69] cell line. Restoration of antioxidant enzyme activity (SOD and CAT) and inhibition of NO production have been shown by astaxanthin in such oxidative stress cell line. In addition, astaxanthin is believed to reduce inflammatory cytokine by its antioxidant property. It possibly inhibits elevated level of pro-inflammatory cytokines by blocking NF-kB activation [69]. Ohgami et al. (2003) investigated the effect of AST on LPS-induced inflammation in vitro and in vivo model. The author demonstrated that AST reduces the elevated NO production and prostaglandin E2 (PGE2) and TNF-α level where L-NAME was used as a positive control. The authors further suggest that reduction of NO production was due to the blocking of NOS enzyme activity similar to the NOS inhibitor L-NAME [70]. NO level was decreased with the treatment of astaxanthin. NO is involved as a neurotransmitter in the CNS which plays an important role in learning and memory. Previous study suggests that NO is released only during training [71]. Role of AST on NO (neurotransmitter) can be investigated during learning session. Since we did not measure the level of NO during training therefore, this result could not explain the effect of AST on signal transmission. However, the reduction of NO that is related with free radical induction is beneficial since neuroprotection is evident in the hippocampus by low level of lipid peroxidation and increased catalase activity.
The AST treatment was given for 6 weeks; from postnatal day 91 to 132 with the intent to reduce the stress level that was enhanced by prenatal LPS exposure in our mice model. This timing of AST treatment was rationally decided after reviewing the previous studies demonstrating neurochemical abnormalities in the adults after prenatal LPS administration [72–74]. In control_AST group, only astaxanthin was given to the animals that were not prenatally LPS-exposed for better comparison and to understand the effect of AST on prenatally LPS-exposed mice. Most of the parameters obtained from the behavioral test (except mobile phase duration in the tail suspension test) and oxidative stress markers were significantly improved in the brain and liver of the control_AST and LPS_AST group. Only the GSH in the liver was not improved by astaxanthin as compared with LPS_AST group, which may be due to improper handling of tissue samples since our previous study as well as several other studies demonstrated a positive effect of AST on GSH in the liver [49, 75–77]. Newman-keuls post hoc test was done to determine the difference between the groups.

The result of the present study showed that astaxanthin treatment reduces a prominent marker of lipid peroxidation (MDA) which is also observed in the ischemic brain injury in adult rats [78]. Wu et al. investigated the protective effect of astaxanthin on D-galactose induced brain aging in rats. The authors demonstrated that astaxanthin treatment restored the activity of SOD, and increased GSH, which is in agreement with our present findings [28]. However, our study has several limitations; we were unable to conduct histology, proteomics, determination of cytokines and neurotransmitter because of lack resources and financial support in our lab. In addition, astaxanthin was given at a single-dose (2 mg/kg) for 6-weeks. Higher or lower dose of astaxanthin could be given to investigate the pharmacological profile of this antioxidant in animal model. Future study may include the determination of the aforesaid compounds to drill down more on the activity of astaxanthin on such prenatal maternal immune activated postnatal behavioral deficits model.

Nevertheless, the present study is novel in many respects. This study first addresses the effect of astaxanthin on the prenatal LPS-exposed behavioral disorder in the adult offspring in vivo model. This study focused on the determination of six oxidative markers. The results of this study open a new avenue to explore the molecular mechanism of antioxidant (AST) in developing behavioral disorders. A further study with co-administration of astaxanthin and LPS in the prenatal stage to observe the protective effect of astaxanthin in the postnatal stage can be initiated.

Conclusions
Prenatally LPS-challenged mice developed behavioral deficits such as depressive and anxiety like symptoms in the adult lives. However, treatment with a potential carotenoid antioxidant astaxanthin in the adult life for a period of 6 weeks showed a significant improvement in the behavioral disorders. We report that astaxanthin treatment possibly benefit depressive and anxiety episodes by reducing oxidative stress. This study thus predicts the potential of astaxanthin in the treatment of neuro-psychiatric disease, but future study should be conducted to explore underpinning mechanisms to ensure the findings.

Authors’ contributions
MMMA participated in the design of the experimental work. SS collected hole-board, open field and tail suspension data. RS and MMR participated in the sacrifice of animals. MMR carried out the biochemical studies, performed the statistical analysis, and drafted the manuscript. MMR performed mice surgery. HMR participated in the design of the experiments, interpreted data and corrected the final version of the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Pharmaceutical Sciences, North South University, Plot 15, Block B, Bashundhara, Dhaka 1229, Bangladesh. 2 The Queensland Brain Institute, The University of Queensland, St. Lucia, Brisbane, QLD-4072, Australia.

Competing interests
The authors declare that they have no competing interests.

Received: 23 August 2015 Accepted: 28 January 2016
Published online: 08 February 2016

References
1. Beloosesky R, Maravi N, Weiner Z, Khattib N, Awad N, Boles J, Ross MG, Itskovitz-Eldor J. Maternal lipopolysaccharide-induced inflammation during pregnancy programs impaired offspring innate immune responses. Am J Obstet Gynecol. 2010;203(2):185 (e181-185, e184).
2. Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci Off J Soc Neurosci. 2007;27(40):10695–702.
3. Shi L, Fatemi SA, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci. 2003;23(1):297–302.
4. Zuckerman L, Rehavi M, Nachman R, Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology. 2003;28(10):1778–89.
5. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006;59(6):546–54.
6. Meyer U, Nyfeler M, Engler A, Urvylye A, Schedlowski M, Krueisler I, Yee BK, Feldon J. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci. 2006;26(18):4752–62.
7. Brown AS, Begg MD, Gravenstein S, Schafer CA, Wyatt RJ, Bresnahan M, Babulak VP, Susser ES. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004;61(8):774–80.
8. Lin YL, Wang S. Prenatal lipopolysaccharide exposure increases depression-like behaviors and reduces hippocampal neurogenesis in adult rats. Behav Brain Res. 2014;259:24–34.
9. Enayati M, Solati J, Hosseini MH, Shahi HR, Saki G, Salari AA. Maternal infection during late pregnancy increases anxiety- and depression-like behaviors with increasing age in male offspring. Brain Res Bull. 2012;82(2–3):295–302.

10. Lin YL, Lin SY, Wang S. Prenatal lipopolysaccharide exposure increases anxiety-like behaviors and enhances stress-induced corticosterone responses in adult rats. Brain Behav Immun. 2012;26(3):459–68.

11. Solati J, Klheemah E, Kratz O, Moll GH, Golub Y. Inverse effects of lipopolysaccharides on anxiety in pregnant mice and their offspring. Physiol Behav. 2015;139:369–74.

12. Chlodzinska N, Gajenska M, Bantkowska K, Turlejski K, Djawadian R. Lipopolysaccharide injected to pregnant mice affects behavior of their offspring in adulthood. Acta Neurobiol Exp. 2011;71(4):519–27.

13. Hao LY, Hao XQ, Li SH, Li XH. Prenatal exposure to lipopolysaccharide results in cognitive deficits in age-increasing offspring rats. Neuroscience. 2010;166(3):763–70.

14. Basta-Kaum A, Budziszewska B, Leskiewicz M, Fijal K, Regulska M, Kubera M, Wzdzony K, Lason W. Hyperactivity of the hypothalamus-pituitary-adrenal axis in lipopolysaccharide-induced neurodevelopmental model of schizophrenia: effects of antipsychotic drugs. Eur J Pharmacol. 2011;650(2–3):586–95.

15. Romero E, Guaza C, Castellano B, Borell J. Ontogenic of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry. 2010;15(4):372–83.

16. Wischhof L, Irrsack E, Osorio C, Koch M. Prenatal LPS-exposure—a developmental rat model of schizophrenia—differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:17–30.

17. Kirsten TB, Chaves-Kirsten GP, Chaible LM, Silva AC, Martins DO, Britto M, Menezes RA. LPS exposure modifies the development of the central dopaminergic system and autistic-like behavior induced by a single early prenatal exposure to lipopolysaccharide. J Neurosci Res. 2012;90(10):1903–12.

18. Foley KA, MacFabe DF, Kavaliers M, Ossenkopp KP. Sexually dimorphic behavioral deficits in mice prenatally challenged with bacterial endotoxin affect anxiety and immune function. Brain Behav Immun. 2014;38:77–90.

19. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Hypoactivity of the central dopaminergic system and autistic-like behavior induced by a single early prenatal exposure to lipopolysaccharide. J Neurosci Res. 2012;90(10):1903–12.

20. Ma L, Liu J, Li N, Wang J, Duan Y, Yan J, Liu H, Wang H, Hong F. Oxidative stress increases anxiety-like behaviors in adult offspring mice following maternal inflammation during pregnancy. J Neurosci Res. 2014;92(2):389–94.

21. Tracey WR, Tse J, Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther. 1995;272(3):1011–11.

22. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descomps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49(5):1304–13.

23. Elman GL, Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7.

24. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7.

25. Kirsten TB, Taricano M, Florio JC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Brain Res Bull. 2010;80(1):77–82.

26. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation. 2010;17(4):240–51.

27. Kirsten TB, Taricano M, Florio JC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Brain Res Bull. 2010;80(1):77–82.

28. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation. 2010;17(4):240–51.

29. Szymanska M, Budziszewska B, Jaworska-Feil L, Basta-Kaim A, Kubera M, Leskiewicz M, Regulska M, Lason W. The effect of antidepressant drugs on the HPA axis activity, glucocorticoid receptor level and FKBP51 expression in prenatally stressed rats. Psychoneuroendocrinology. 2013;38:55–65.

30. Al-Amin MM, Hasan SM, Alam MA, Rahman MM. Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice. Eur J Pharmacol. 2014;745:84–90.

31. Heineus WG, Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem. 1968;6(11):126–30.

32. Sinha AK. Colorimetric assay of catalase. Anal Biochem. 1972;47(2):389–94.

33. Tracey WR, Tse J, Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther. 1995;272(3):1011–11.

34. Kirsten TB, Taricano M, Florio JC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Brain Res Bull. 2010;80(1):77–82.

35. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation. 2010;17(4):240–51.

36. Kirsten TB, Taricano M, Florio JC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Brain Res Bull. 2010;80(1):77–82.

37. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation. 2010;17(4):240–51.

38. Kirsten TB, Taricano M, Florio JC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Brain Res Bull. 2010;80(1):77–82.

39. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation. 2010;17(4):240–51.

40. Kirsten TB, Taricano M, Florio JC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Brain Res Bull. 2010;80(1):77–82.
49. Al-Amin MM, Rahman MM, Khan FR, Zaman F, Reza HM. Astaxanthin improves behavioral memory and oxidative stress in rats. Behav Brain Res. 2015;286:112–21.

50. Sebai H, Gadacha W, Sani M, Aouani E, Ghafen-Boughanim N, Ben-Atta M. Protective effect of resveratrol against lipopolysaccharide-induced oxidative stress in rat brain. Brain Injury (BI). 2009;23(13–14):1089–94.

51. Stuss M, Wiktorowska JA. Severeyniek E. N-acetylcysteine reduces lipopolysaccharide-induced lipid peroxidation in vitro more effectively than melatonin. Neuro Endocrinol Lett. 2010;31(4):489–96.

52. Severeyniek E, Wiktorowska JA, Stuss M. 6-methoxytryptophol reduces lipopolysaccharide-induced lipid peroxidation in vitro more effectively than melatonin. J Physiol pharmacol Off J Polish Physiol Soc. 2011;62(6):677–83.

53. Franceschelli S, Pesce M, Ferrone L, Marenco ML, Zappulli L, Nastasi A. LPS administration confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide. In vitro study. J Biol. 2015;950(4):483–9.

54. Requintina PJ, Oxenkrug GF. Differential effects of lipopolysaccharide on oxidative stress in monocytes from HIV+ patients. Immunology. 2003;108(3):265–72.

55. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Landers TM, Carvey PM. In vivo effects of free form astaxanthin on lipid peroxidation in F344 N, SHR rats and BALB/c mice, and protection of melatonin and NAS against its toxicity. Ann NY Acad Sci. 2003;993.325–33

(discussion 345–329)

56. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS, Carvey PM. Lipopolysaccharide-induced cellular death is mediated by accumulation of reactive oxygen species and activation of p38 in rat cortex and hippocampus. Exp Neurol. 2003;184(2):794–804.

57. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci. 2003;5(1):116–24.

58. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P. HDAC1 expression is elevated in neurons undergoing excitotoxic cell death in vivo and in vitro. J Neurosci. 2015;35(1):116–22.

59. Kirsten TB, Queiroz-Hazarbassanov N, Bernardi MM, Felicito LF. Prenatal zinc prevents communication impairments and BDNF disturbance in a rat model of autism induced by prenatal lipopolysaccharide exposure. Life Sci. 2015;130:12–7.

60. Bautista AP, Meszaros K, Bojta J, Spitzer JJ. Superoxide anion generation in the liver during the early stage of endotoxemia in rats. J Leukoc Biol. 1990;48(2):123–8.

61. Wang T, Qiu L, Liu B, Liu Y, Wilson B, Elbing TE, Langenbach R, Tanaiu S, Hong JS. Role of reactive oxygen species in LPS-induced cell death. J Biol. 2003;184(2):794–804.

62. Paintlia MK, Paintlia AS, Barbosa E, Singh I, Singh AK. N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hyposynaptogenesis in developing rat brain. J Neurosci Res. 2004;78(2):547–61.

63. Mayer AM. Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. Medica. 1998;38(4):77–85.

64. Nolan Y, Verek E, Lynch AM, Lynch MA. Evidence that lipopolysaccharide-induced cell death is mediated by accumulation of reactive oxygen species and activation of p38 in rat cortex and hippocampus. Exp Neurol. 2003;184(2):794–804.

65. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 2002;941(1–2):1–10.

66. Ling Z, Chang QA, Tong CW, Leurgans SE, Lipton JW, Carvey PM. Roterone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Exp Neurol. 2004;190(2):373–83.

67. Yazar E, Er A, Uney K, Bulbul A, Avci GE, Elmas M, Tras B. Effects of drugs used in endotoxic shock on oxidative stress and organ damage markers. Free Radical Res. 2010;44(4):397–402.

68. Thomas JP, Mairimma M, Ursini F, Gottri AI. Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. J Biol Chem. 1990;265(1):454–61.

69. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing IkappaB kinase-dependent NF-kappaB activation. Mol Cells. 2003;16(1):97–105.

70. Ohgami K, Shiratori K, Kato H, Nishida T, Mizuki N, Yazawa K, Ohno S. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003;44(6):2694–701.

71. Harooni HE, Naghdi N, Sepehri H, Rohani AH. The role of hippocampal nitric oxide (N0) on learning and immediate, short- and long-term memory retrieval in inhibitory avoidance task in male adult rats. Behav Brain Res. 2009;201(1):166–72.

72. Kirsten TB, Queiroz-Hazarbassanov N, Bernardi MM, Felicito LF. Prenatal zinc prevents communication impairments and BDNF disturbance in a rat model of autism induced by prenatal lipopolysaccharide exposure. Life Sci. 2015;130:12–7.

73. Wang S, Yan JY, Lo YK, Carvey PM, Ling Z. Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Res. 2009;1265:196–204.

74. Ling ZD, Chang Q, Lipton JW, Tong CW, Landers TM, Carvey PM. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience. 2004;124(3):619–28.

75. Chen YY, Lee PC, Wu YL, Liu LY. In vivo effects of free form astaxanthin powder on anti-oxidation and lipid metabolism with high-cholesterol diet. PLoS One. 2015;10(8):e0134733.

76. Sila A, Kamoun Z, Ghilissi Z, Makni M, Nasri M, Sahnoun Z, Nedjar-Arroume N, Bougafef A. Ability of natural astaxanthin from shrimp by-products to attenuate liver oxidative stress in diabetic rats. Pharmacol Rep. 2015;67(2):310–6.

77. Kang JO, Kim SJ, Kim H. Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of C4H-treated rats. Methods Find Exp Clin Pharmacol. 2001;23(3):79–84.

78. Shen H, Kuo C-C, Chou J, Delvolve A, Jackson SN, Post J, Woods AS, Hoffer BJ, Wang Y, Harvey BK. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009;23(6):1958–68.